Fit Over 40 Join the community

HRT black box warning removed: what the FDA changed by product type, what stayed, and what the evidence shows

Headlines said the FDA removed the black box warning on hormone therapy. The real change is narrower: it depends on the product, and some warnings stayed. This guide sorts out what the FDA changed, which products have new labels as of November 2026, what the underlying trials show, and why the change is contested.

Researched and drafted by the Fit Over 40 editorial team. Last updated November 12, 2026. 8 minute read. How we research
Older woman stretching on a beach

The short version

  • The FDA change is product by product. The agency asked for new labels in November 2025, approved the first six products on February 12, 2026 and three estradiol patches on October 30, 2026. Nine products are on its list, and 29 companies have submitted proposed changes.
  • By category: the boxed warning is removed entirely for estrogen-plus-progestogen products and local vaginal estrogen. For systemic estrogen-alone products, the endometrial cancer boxed warning stays.
  • Not changed: heart disease and breast cancer information remains in the label outside the box, approved uses are the same, and hormone therapy is not meant to prevent heart disease. Whether it prevents dementia is unknown.
  • The trial numbers did not change. In the Women's Health Initiative, estrogen plus progestin meant 12 excess serious events per 10,000 women a year at ages 50 to 59, and estrogen alone meant 19 fewer. A 2019 meta-analysis put the breast cancer relative risk at 2.08 for years 5 to 14 of estrogen plus progestagen.
  • The process is contested. Critics, including Public Citizen and former WHI safety monitors, cite an ad hoc panel and no new safety data. Supporters, including panel members, the Menopause Society and ACOG, say the class-wide warning overstated risk, especially for vaginal estrogen.
  • Access: in October 2026 HHS reported localized difficulty finding usual estradiol patches, said it knows of no imminent nationwide shortage, and said patch output has roughly doubled in 12 months.

What the FDA changed, by product type

The FDA began adding warnings to estrogen products in 2003, and those later became the boxed warning.1 In November 2025 it asked makers to rewrite the labels, and it approves each change product by product.2,3 The table shows what the agency requested for each type of product. Status is current as of November 12, 2026, based on the FDA list dated October 30, 2026.

Product typeBoxed warning on updated labelsOther label changes
Systemic estrogen plus progestogenRemoved entirely: cardiovascular disease, breast cancer, probable dementia and endometrial cancer language, plus the "lowest effective dose" recommendation2Probable dementia warning removed from the whole label. New language to consider starting for moderate to severe hot flashes in women under 60 or within 10 years of menopause. WHI data for ages 50 to 59 added. Cardiovascular and breast cancer information stays elsewhere in the label2
Systemic estrogen aloneEndometrial cancer boxed warning kept. The cardiovascular, breast cancer and dementia language is removed2,4Same additions as above2
Local vaginal estrogenRemoved entirely2,4Probable dementia warning removed. Safety information condensed to what is most relevant to local use2

Source: FDA requested labeling changes. Public Citizen's summary of the February 2026 approvals confirms the same split.4

DateEvent
July 17, 2025FDA holds an expert panel on menopause and hormone therapy2
November 10, 2025HHS and FDA announce the label request. FDA leaders publish a JAMA viewpoint describing the rationale2,5
February 12, 2026First six products approved with updated labels: Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva6,3
February 2026Former WHI data and safety monitoring board members publish a JAMA viewpoint arguing labels should rely on evidence, not opinion7
October 30, 2026Three estradiol patches approved, bringing the total to nine. FDA says 29 companies have submitted proposed changes8,3

The FDA list as of October 30, 2026 includes Minivelle, Vivelle and Vivelle-Dot alongside the six from February. Premarin, Prempro, Estrace and Climara were not on it.3 Products that are not listed still carry their previous labels.

Need more than general advice? Our community offers professional, personalized nutrition and exercise plans. Join the Fit Over 40 community

What did not change

  • The endometrial cancer boxed warning remains on whole-body estrogen-only products.1,2 The Medical Letter notes that women with a uterus who use systemic estrogen should also receive a progestin, or the drug bazedoxifene, to protect the uterine lining.9
  • Heart disease and breast cancer risks are still described in the label, outside the box.1,2
  • The approved uses are hot flashes, vulvovaginal symptoms (now called genitourinary syndrome of menopause) and, for some products, prevention of postmenopausal osteoporosis.2
  • It is not meant to be taken just to prevent heart disease, and experts do not yet know whether it prevents dementia.1
  • The Women's Health Initiative (WHI) investigators take no position on the box itself. They say their conclusion stands: oral hormone therapy should not be used for chronic disease prevention, and it can be reasonable for moderate to severe hot flashes at the lowest dose for the shortest time needed.7

What the trials show behind each removed warning

The boxed warning rested largely on two WHI trials of one oral estrogen (conjugated equine estrogens) and one progestin (medroxyprogesterone acetate) in women who averaged 63 years old.1 The table lines up what the data say for each risk that came out of the box.

Removed warningWhat the data showType of evidence
Cardiovascular diseaseWHI found that oral therapy raised the risk of stroke and blood clots and did not prevent heart attacks.7 On the trials' global index, a composite of serious outcomes, estrogen plus progestin meant 12 excess cases per 10,000 women a year at ages 50 to 59 and 38 at 70 to 79. Estrogen alone meant 19 fewer cases at 50 to 59 and 51 excess at 70 to 79.10 After 18 years, all-cause mortality was 27.1% with hormone therapy and 27.6% with placebo (hazard ratio 0.99).11Randomized trials of oral therapy. Age results are subgroup analyses
Breast cancerWHI found more breast cancer with estrogen plus progestin.1 A 2019 meta-analysis found excess risk for every type except vaginal estrogen. Relative risk for current users was 1.60 (estrogen plus progestagen) and 1.17 (estrogen alone) in years 1 to 4, and 2.08 and 1.33 in years 5 to 14.12 The authors estimated that five years of daily estrogen plus progestagen from age 50 would raise 20-year risk at ages 50 to 69 from 6.3% to 8.3%.12 In WHI women aged 50 to 59, estrogen alone showed a nominal reduction in breast cancer, unlike the observational pattern.13Observational meta-analysis, plus randomized subgroup data
Probable dementiaThe WHI dementia studies enrolled women aged 65 to 79.2,1 Oral therapy raised dementia rates in women over 65.7 Whether hormone therapy prevents dementia is unknown.1 One expert told Healio there is no randomized evidence that it reduces heart disease or cognitive decline.5Randomized trials in older women. No trial of starting near menopause

Age matters in these numbers, but the sample is thin. In WHI women aged 50 to 59, conjugated estrogens alone lowered a composite of serious outcomes (hazard ratio 0.82, 95% CI 0.71 to 0.95), yet the authors note that the number of women with important outcomes stays small in this age group, leaving an unclear balance of risks and benefits.13 WHI did not test skin patches or vaginal products, and no large randomized trials of non-oral forms exist.7 The Medical Letter notes that commonly used estrogens today are often given through the skin or vagina to bypass the liver and reduce clot risk, which is a reasoned expectation rather than a trial result.9

Why the change is contested

The FDA's case. The agency says its request followed a literature assessment, updated drug-use data, public input including the July 2025 panel, and further analyses of WHI follow-up.2 In a JAMA viewpoint, FDA leaders wrote that the changes allow more nuanced communication by formulation and population, and that the changes may reduce fear that has kept about 50 million women from the therapy's benefits.5 Most panel members argued that WHI results do not apply to modern regimens such as low-dose vaginal estrogen and estradiol, and supported revising the box or removing it for vaginal estrogen.14 The FDA had rejected a 2018 petition to remove the vaginal estrogen warning, citing a lack of safety evidence, according to CNN.15

Support with limits. The Menopause Society agreed with removing the box from low-dose vaginal estrogen, adding that systemic estrogen still carries risks to review with each woman, and that those risks are low for younger, healthy women who start near menopause.16 ACOG's president said the changes support shared decision-making and that ACOG's estrogen guidance is unchanged.5

The critics' case. Public Citizen says the decision rested on opinion, not new safety data. It also says the FDA's literature review did not appear to be public as of late February 2026 and that the agency used an ad hoc panel instead of a formal advisory committee. It cites former WHI safety monitors who wrote that panelists had about five minutes each and none voiced an opposing view, and it asks the FDA to convene a formal panel.4 The WHI site says no similarly large randomized trials since WHI would change the risk-benefit balance for oral therapy.7 Nanette Santoro, a University of Colorado physician, told Healio she was surprised the box was removed entirely and that some announcement statements go beyond the data.5 For the October 2026 patch approvals, The Guardian reported that the FDA held no advisory committee meeting beforehand.17 CNN noted that the JAMA viewpoint is not the detailed review of studies regulators usually undertake.15

Access: patches, supply and vaginal estrogen

On October 30, 2026 HHS said the FDA expected demand for estradiol patches to rise after the label update and was working with all six patch manufacturers. Output has roughly doubled over the past 12 months, and the FDA says it is not aware of an imminent nationwide shortage. HHS also reported localized difficulty finding the usual patch product, with availability varying by brand, strength, once-weekly or twice-weekly format, and location. The agency is monitoring gels and creams, approving generics including a once-weekly patch, and working with sponsors to explore over-the-counter availability of vaginal estrogen, which would require FDA approval.8

What we still do not know

  • Whether skin and vaginal estrogens carry lower stroke, clot and breast cancer risks than the oral regimens WHI tested. WHI did not study them, and no large randomized trials exist.7
  • What the FDA's literature review concluded in full. Critics said it was not public as of February 2026.4
  • Whether starting hormone therapy near menopause lowers heart disease or dementia risk. One expert says no randomized trial shows it.5
  • How the remaining labels will read. Only nine products were on the FDA list on October 30, 2026, while 29 companies have submitted changes.3,8
  • How the changes alter prescribing. Commentators expect more use among perimenopausal and younger postmenopausal women, and some clinicians say more questions need answers as warnings come off.9,17

Questions to take to your clinician

  • Which product and route am I considering (pill, patch, gel or vaginal), and what does that exact product's current label say?
  • Do I need a progestogen with it, and why?
  • How do my own heart disease and breast cancer risks shape the choice?
  • If my usual patch is out of stock, what is the equivalent dose and format?

Related guides:

Common questions

Did the FDA remove the black box warning on hormone therapy?

Partly, and product by product. In November 2025 the FDA asked for the heart disease, breast cancer and probable dementia language to come out of the boxed warning, and it kept the endometrial cancer warning on systemic estrogen-alone products.1,2 As of its October 30, 2026 list, nine products had approved updated labels.3,8

Which hormone therapy products have the new label?

FDA's list as of October 30, 2026 names Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva, approved February 12, 2026, plus three estradiol patches: Minivelle, Vivelle and Vivelle-Dot. Premarin, Prempro, Estrace and Climara were not on it.3,6

Does the boxed warning still apply to estrogen-only therapy?

Yes, for systemic estrogen-alone products, which keep a boxed warning about endometrial cancer.1,2 The Medical Letter notes that women with an intact uterus who use systemic estrogen should also receive a progestin or bazedoxifene for endometrial cancer protection.9

What happened to the warning on vaginal estrogen?

The FDA requested removal of the entire boxed warning from local vaginal estrogen, with a condensed safety section focused on local use.2 The Menopause Society agreed, saying the box may have deterred use of low-dose vaginal estrogen.16 In October 2026 HHS said FDA is working with sponsors to explore over-the-counter vaginal estrogen, which would need FDA approval.8

Does hormone therapy cause breast cancer?

A 2019 meta-analysis of epidemiological studies found excess breast cancer risk with every type except vaginal estrogen. Relative risks were 1.60 for estrogen plus progestagen and 1.17 for estrogen alone in the first 1 to 4 years of current use, rising to 2.08 and 1.33 at 5 to 14 years.12 In WHI, estrogen plus progestin raised breast cancer risk,1 while among women aged 50 to 59 estrogen alone showed a nominal reduction.13

Does hormone therapy prevent dementia or heart disease?

That has not been shown. The Office on Women's Health says hormone therapy is not meant to be taken just to prevent heart disease and that experts do not yet know whether it prevents dementia.1 The WHI investigators say oral hormone therapy should not be used for chronic disease prevention.7

What age does the new label language point to?

For systemic products, the FDA asked for language about considering therapy for moderate to severe hot flashes in women under 60 or within 10 years of menopause, and for WHI data on women aged 50 to 59 to be added.2

Is there an estrogen patch shortage?

In October 2026 HHS reported localized difficulty finding usual patch products but said the FDA is not aware of an imminent nationwide shortage. Patch output has roughly doubled in 12 months, and availability varies by brand, strength and dosing schedule.8

References

  1. Office on Women's Health. Hormone therapy safety (womenshealth.gov; last updated October 23, 2026). https://womenshealth.gov/menopause/hormone-therapy-safety
  2. US Food and Drug Administration. FDA requests labeling changes related to safety information to clarify the benefit/risk considerations for menopausal hormone therapies. Announced November 10, 2025; page updated February 12, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations
  3. US Food and Drug Administration. Menopausal hormone therapies with updated prescribing information (content current as of October 30, 2026). https://www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information
  4. Zeldes N, Steinbrook R. Outrage of the month: labeling changes to menopausal hormone therapy products. Public Citizen Health Letter. March 2026. https://citizen.org/article/outrage-of-the-month-labeling-changes-to-menopausal-hormone-therapy-products
  5. Healio. HHS revises hormone therapy black box warning for menopause treatment (coverage of Makary MA, et al. Updated labeling for menopausal hormone therapy. JAMA, online November 10, 2025). November 10, 2025. https://www.healio.com/news/womens-health-ob-gyn/20251110/hhs-revises-hormone-therapy-black-box-warning-for-menopause-treatment
  6. US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products (news release). February 12, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
  7. Women's Health Initiative. WHI responds to FDA removal of black box warning on hormonal therapies (November 12, 2025; updated February 2026). https://www.whi.org/md/news/whi-fda-hrt-warning
  8. US Department of Health and Human Services. FDA advances menopause care: hormone therapy labeling and access (press release). October 30, 2026. https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html
  9. The Medical Letter on Drugs and Therapeutics. In brief: label changes for menopausal hormone therapy products. Med Lett Drugs Ther. 2026;68(1748):30-31. https://secure.medicalletter.org/TML-article-1748d
  10. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. https://escholarship.org/uc/item/9wm2j4gt
  11. Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938. https://doi.org/10.1001/jama.2017.11217
  12. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-1168. https://pmc.ncbi.nlm.nih.gov/articles/6891893
  13. Prentice RL, Aragaki AK, Chlebowski RT, et al. Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50-59 years of age. Am J Epidemiol. 2021;190(3):365-375. https://pmc.ncbi.nlm.nih.gov/articles/PMC8086238
  14. Patient Care Online. FDA advisory panel calls for revised class labeling for menopausal hormone replacement therapy (July 17, 2025 panel). July 24, 2025. https://www.patientcareonline.com/view/fda-advisory-panel-urges-revised-black-box-warnings-on-hormone-replacement-therapy
  15. CNN Health (syndicated). US health leaders hailed the benefits of hormone therapy for menopause. Doctors are pushing for balance. November 12, 2025. https://abc17news.com/cnn-health/2025/11/12/us-health-leaders-hailed-the-benefits-of-hormone-therapy-for-menopause-doctors-are-pushing-for-balance/
  16. The Menopause Society. The Menopause Society comments on the FDA announcement on hormone therapy. November 2025. https://menopause.org/press-releases/the-menopause-society-comments-on-the-fda-announcement-on-hormone-therapy
  17. Contemporary OB/GYN. Reactions to FDA's boxed warning removals for menopausal hormone therapy. November 2, 2026. https://www.contemporaryobgyn.net/view/reactions-fda-boxed-warning-removals-menopausal-hormone-therapy
About this article

Every health claim above links to its source. It is general information and cannot take your personal history into account, so use it to prepare for a conversation with your own clinician.

Spotted an error? Tell us and we will check it.

Keep reading